Clinical Trial Update: Tislelizumab Combined With XELOX as Neoadjuvant Therapy for G/GEJ Adenocarcinoma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating tislelizumab combined with XELOX as neoadjuvant therapy for locally advanced gastric or gastroesophageal junction adenocarcinoma has co…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Adenocarcinoma
• Gastric Cancer
• Gastroesophageal Junction Cancer

Drugs mentioned

• Capecitabine (capecitabine)
• OXALIPLATIN (Oxaliplatin)
• Tislelizumab (tislelizumab)

Snippet

Sponsor: Xijing Hospital | Conditions: Locally Advanced Gastric Adenocarcinoma | Phase 2 | Status: COMPLETED